

Research articles

1. Efecto de la administración de L-dopa sobre la liberación de insulina en los islotes pancreáticos de rata. **Fernández-Ruiz, J.J.**; Tamarit Rodriguez, J.; Ramos, J.A. N. Arch. Fac. Med. 41 : 507-512 (1983).
2. Catecholaminergic modulation of the prolactin secretion in normal and pituitary grafted male rats. **Fernández-Ruiz, J.J.**; Ubeda, E.; Tresguerres, J.A.F.; Esquifino, A.I.; Ramos, J.A. IRCS Medical Science 13 : 1126-1127 (1985).
3. Effect of experimentally induced hyperprolactinemia on thyroid function in male rats. Agrasal, C.; Esquifino, A.I.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Ramos, J.A.; Tresguerres, J.A.F. IRCS Medical Science 13 : 1128-1129 (1985).
4. Modifications of plasma prolactin levels and catecholamine content in an ectopic anterior pituitary gland transplanted under the kidney capsule. **Fernández-Ruiz, J.J.**; Ubeda, E.; Cebeira, M.; Agrasal, C.; Tresguerres, J.A.F.; Ramos, J.A.; Esquifino, A.I. Hormone Research 25 : 105-112 (1987).
5. Effect of elevated prolactin levels on the synthesis and release of catecholamines from the adrenal medulla in female rats. **Fernández-Ruiz, J.J.**; Cebeira, M.; Agrasal, C.; Tresguerres, J.A.F.; Esquifino, A.I.; Ramos, J.A. Neuroendocrinology 45 : 208-211 (1987).
6. Possible role of dopamine and noradrenaline in the regulation of prolactin secretion from an ectopic anterior pituitary gland in female rats. **Fernández-Ruiz, J.J.**; Cebeira, M.; Agrasal, C.; Bartke, A.; Tresguerres, J.A.F.; Esquifino, A.I.; Ramos, J.A. Journal of Endocrinology 113 : 45-49 (1987).
7. Prolactin increases norepinephrine and dopamine turnover in the median-eminence of hypophysectomized female rats. Esquifino, A.I.; **Fernández-Ruiz, J.J.**; Bartke, A.; Agrasal, C.; Steger, R.W.; Cebeira, M. Neuroendocrinology Letters 9 : 5-14 (1987).
8. Presence of tyrosine-hydroxylase activity in anterior pituitary adenomas and ectopic anterior pituitaries in male rats. **Fernández-Ruiz, J.J.**; Esquifino, A.I.; Steger, R.W.; Amador, A.G.; Bartke, A. Brain Research 421 : 65-68 (1987).
9. Catecholaminergic control of plasma growth hormone and thyrotropin levels in hypophysectomized rats bearing ectopic pituitary transplants. Esquifino, A.I.; Agrasal, C.; Steger, R.W.; **Fernández-Ruiz, J.J.**; Ramos, J.A.; Cebeira, M.; Bartke, A. Life Sciences 41 : 1043-1050 (1987).
10. Effect of experimentally induced hyperprolactinemia on growth hormone secretion. Esquifino, A.I.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Agrasal, C.; Tresguerres, J.A.F.; Ramos, J.A. Revista Española de Fisiología 43 : 463-468 (1987).
11. Involvement of endogenous catecholamines in the control of prolactin secretion from ectopic pituitary transplants in hypophysectomized female rats. **Fernández-Ruiz, J.J.**; Agrasal, C.; Steger, R.W.; Chandrashekar, V.; Cebeira, M.; Ramos, J.A.; Bartke, A.; Esquifino, A.I. Neuroendocrinology Letters 9 : 237-247 (1987).
12. Physiologic and morphologic changes in rat anterior pituitaries separated of the normal brain control. Jiménez de Blas, L.; **Fernández-Ruiz, J.J.**; Rúa, C.; Muñiz, E.; Agrasal, C.; Cebeira, M. Neuroendocrinology Letters 9 : 353-361 (1987).
13. Role of estrogens on striatal dopaminergic activity. Ramos, J.A.; Pais, J.R.; Cebeira, M.; **Fernández-Ruiz, J.J.** Journal of Steroid Biochemistry 27 : 683-689 (1987).
14. Changes in catecholamine metabolism in adrenal medulla of adult male rats with experimentally induced hyperprolactinemia. Bukhari, A.R.; **Fernández-Ruiz, J.J.**; Pais, J.R.; Alvarez-Sanz, C.; Ramos, J.A. Biogenic Amines 5 : 103-109 (1988).
15. Decreased dopamine turnover in striatum of female rats bearing ectopic pituitaries or with bilateral ovariectomy. **Fernández-Ruiz, J.J.**; Pais, J.R.; Cebeira, M.; Ramos, J.A. Biogenic Amines 5 : 115-123 (1988).
16. Effects of estrogens and progesterone on the catecholaminergic activity of the adrenal medulla in

- female rats. **Fernández-Ruiz, J.J.**; Bukhari, A.R.; Martínez-Arrieta, R.; Tresguerres, J.A.F.; Ramos, J.A. Life Sciences 42 : 1019-1028 (1988).
17. Effects of prolactin on the adrenal medulla in mice and hamsters. **Fernández-Ruiz, J.J.**; Esquifino, A.I.; Steger, R.W.; Bartke, A.; Hodges, S. Neuroendocrinology Letters 10 : 5-13 (1988).
 18. Insulin binding and action on adipocytes from female rats with experimentally-induced chronic hyperprolactinemia. Cabrera, R.; Mayor, P.; **Fernández-Ruiz, J.J.**; Calle, C. Molecular and Cellular Endocrinology 58 : 167-173 (1988).
 19. Effects of estradiol on circulating levels of prolactin in female rats bearing ectopic pituitaries. **Fernández-Ruiz, J.J.**; Agrasal, C.; Cebeira, M.; Tresguerres, J.A.F.; Esquifino, A.; Ramos, J.A. Revista Española de Fisiología 44 : 205-210 (1988).
 20. Possible role of dopaminergic, noradrenergic and serotonergic hypothalamic neurons on hyperprolactinemia-induced changes in growth hormone secretion. Agrasal, C.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Tresguerres, J.A.F.; Ramos, J.A.; Esquifino, A.I. Biogenic Amines 5 : 397-404 (1988).
 21. Possible direct effect of prolactin on catecholamine synthesis and release in rat adrenal medulla: in vitro studies. **Fernández-Ruiz, J.J.**; Martínez-Arrieta, R.; Hernández, M.L.; Ramos, J.A. Journal of Endocrinological Investigation 11 : 603-608 (1988).
 22. Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2 receptors. **Fernández-Ruiz, J.J.**; Amor, J.C.; Ramos, J.A. Brain Research 476 : 388-395 (1989).
 23. 2-Hydroxyestradiol is not mediating the effects of estradiol on tuberoinfundibular dopaminergic neurons controlling prolactin release in female rats. **Fernández-Ruiz, J.J.**; Alvarez-Sanz, C.; Ramos, J.A. Journal of Steroid Biochemistry 32 : 71-75 (1989).
 24. Prolonged neuroendocrine effects of a brief exposure of adult male rats to diethylstilbestrol. Steger, R.; Esquifino, A.; **Fernández-Ruiz, J.J.**; Bartke, A. Neuroendocrinology 49 : 191-196 (1989).
 25. Possible role of hypothalamic biogenic amines on hyperprolactinemia-induced changes of thyrotropin hormone secretion. Agrasal, C.; Cebeira, M.; **Fernández-Ruiz, J.J.**; Ramos, J.A.; Tresguerres, J.A.F.; Esquifino, A.I. Biogenic Amines 6 : 315-322 (1989).
 26. Changes in the catecholamine metabolism in the adrenal medulla of male hamsters with experimental hyperprolactinemia. **Fernández-Ruiz, J.J.**; Esquifino, A.I.; Steger, R.W.; Bukhari, A.R.; Bartke, A. Comparative Biochemistry and Physiology 93C : 303-306 (1989).
 27. Sex- and age-related changes in catecholamine metabolism and release of rat adrenal gland. **Fernández-Ruiz, J.J.**; Bukhari, A.R.; Hernández, M.L.; Alemany, J.; Ramos, J.A. Neurobiology of Aging 10 : 331-335 (1989).
 28. Role of ovarian steroids on the synthesis and release of catecholamines from female rat adrenal: in vivo and in vitro studies. de Miguel, R.; **Fernández-Ruiz, J.J.**; Hernández, M.L.; Ramos, J.A. Life Sciences 44 : 1979-1986 (1989).
 29. Regulation of GH and TSH release from hyperplastic and ectopic pituitaries: effects of dopamine in vitro. Esquifino, A.I.; Agrasal, C.; Steger, R.W.; **Fernández-Ruiz, J.J.**; Amador, A.G.; Bartke, A. Life Sciences 45 : 199-206 (1989).
 30. Effects of diethylstilbestrol (DES) on testicular function and luteinizing hormone receptors. Amador, A.G.; Esquifino, A.I.; Bartke, A.; Chandrashekar, V.; **Fernández-Ruiz, J.J.**; Steger, R.W.; Hodges, S.L. Revista Española de Fisiología 45 : 245-254 (1989).
 31. Changes in brain dopaminergic indices induced by perinatal exposure to cannabinoids in rats. Rodríguez de Fonseca, F.; Cebeira, M.; Hernández, M.L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Developmental Brain Research 51 : 237-240 (1990).
 32. Effects of estrogen and ectopic pituitary transplants on the responsiveness of pituitary prolactin release to luteinizing hormone-releasing hormone and dopamine. Esquifino, A.I.; Steger, R.W.;

- Fernández-Ruiz, J.J.**; Bartke, A.; Amador, A.G.; Chandrashekar, V. Journal of Neuroendocrinology 2 : 145-149 (1990).
33. Time-course of the effects of ovarian steroids on the activity of limbic and striatal dopaminergic neurons in female rat brain. **Fernández-Ruiz, J.J.**; de Miguel, R.; Hernández, M.L.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 36 : 603-606 (1990).
 34. Prolactin inhibits the activity of tyrosine hydroxylase in cultured bovine adrenal chromaffin cells in a dose-dependent manner. Hernández, M.L.; de Miguel, R.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Brain Research 528 : 175-178 (1990).
 35. Effects of dopamine on prolactin release from ectopic and hyperplastic anterior pituitaries: changes at receptor and postreceptor level. **Fernández-Ruiz, J.J.**; Cebeira, M.; Rodríguez de Fonseca, F.; Ramos, J.A. Neuroendocrinology Letters 12 : 455-463 (1991).
 36. Time-dependent effects of ovarian steroids on tyrosine hydroxylase activity in the limbic forebrain of female rats. Hernández, M.L.; **Fernández-Ruiz, J.J.**; de Miguel, R.; Ramos, J.A. Journal of Neural Transmission 83 : 77-84 (1991).
 37. Lack of effect of prolactin on the dopaminergic receptor sensitivity in striatal and limbic areas after experimentally-induced alterations in its peripheral levels. Cebeira, M.; Hernández, M.L.; Rodríguez de Fonseca, F.; de Miguel, R.; **Fernández-Ruiz, J.J.**; Ramos, J.A. Life Sciences 48 : 531-541 (1991).
 38. Is prolactin playing a role in the regulation of the catecholamine synthesis and release from male rat adrenal medulla?. Hernández, M.L.; de Miguel, R.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Journal of Endocrinological Investigation 14 : 201-208 (1991).
 39. Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Rodríguez de Fonseca, F.; Cebeira, M.; **Fernández-Ruiz, J.J.**; Navarro, M.; Ramos, J.A. Neuroscience 43 : 713-723 (1991).
 40. Nigrostriatal and mesolimbic dopaminergic activities were modified throughout the ovarian cycle of female rats. **Fernández-Ruiz, J.J.**; Hernández, M.L.; de Miguel, R.; Ramos, J.A. Journal of Neural Transmission 85 : 223-229 (1991).
 41. Time-course of the effects of ovarian steroids on pituitary prolactin release: lack of correlation with the changes in the activity of tuberoinfundibular dopaminergic neurons. de Miguel, R.; **Fernández-Ruiz, J.J.**; Hernández, M.L.; Ramos, J.A. Neuroendocrinology Letters 13 : 67-73 (1991).
 42. Effects of Δ^9 -tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Rodríguez de Fonseca, R.; **Fernández-Ruiz, J.J.**; Murphy, L.L.; Eldridge, J.C.; Steger, R.W.; Bartke, A. Pharmacology, Biochemistry & Behavior 40 : 593-598 (1991).
 43. Prolonged effects of persistent hyperprolactinemia on adrenal medullary function in male rats. **Fernández-Ruiz, J.J.**; Cebeira, M.; Steger, R.W.; Rodríguez de Fonseca, F.; Murphy, L.; Bartke, A. Biogenic Amines 8 : 69-78 (1991).
 44. Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids. Rodríguez de Fonseca, F.; Hernández, M.L.; de Miguel, R.; **Fernández-Ruiz, J.J.**; Ramos, J.A. Pharmacology, Biochemistry & Behavior 41 : 469-474 (1992).
 45. Comparison between brain dopaminergic neurons of juvenile and aged rats: sex-related differences. **Fernández-Ruiz, J.J.**; de Miguel, R.; Hernández, M.L.; Cebeira, M.; Ramos, J.A. Mechanisms of Ageing and Development 63 : 45-55 (1992).
 46. Acute effects of Δ^9 -tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Rodríguez de Fonseca, R.; **Fernández-Ruiz, J.J.**; Murphy, L.L.; Cebeira, M.; Steger, R.W.; Bartke, A.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 42 : 269-275 (1992).
 47. Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice. Navarro, M.; **Fernández-Ruiz, J.J.**; Rodríguez de Fonseca, F.; Hernández, M.L.; Cebeira, M.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 43 : 603-608

(1992).

48. Estrogenic modulation of Δ^9 -tetrahydrocannabinol effects on the nigrostriatal dopaminergic activity in the female rat brain. Bonnin, A.; **Fernández-Ruiz, J.J.**; Martín, M.; Rodríguez de Fonseca, F.; de Miguel, R.; Ramos, J.A. Molecular and Cellular Neurosciences 3 : 315-325 (1992).
49. Neuroendocrine effects of an acute dose of Δ^9 -tetrahydrocannabinol: changes in hypothalamic biogenic amines and anterior pituitary hormone secretion. **Fernández-Ruiz, J.J.**; Navarro, M.; Hernández, M.L.; Vaticón, D.; Ramos, J.A. Neuroendocrinology Letters 14 : 349-355 (1992).
50. Δ^9 -Tetrahydrocannabinol administration affects anterior pituitary, corticoadrenal and adrenomedullary functions in male rats. Rodríguez de Fonseca, F.; Murphy, L.L.; Bonnin, A.; Eldridge, J.C.; Bartke, A.; **Fernández-Ruiz, J.J.** Life Science Advances 11 : 147-156 (1992).
51. Presence of cannabinoid binding sites in the brain from early postnatal ages. Rodríguez de Fonseca, F.; Ramos, J.A.; Bonnin, A.; **Fernández-Ruiz, J.J.** Neuroreport 4 : 135-138 (1993).
52. Motor disturbances induced by an acute dose of Δ^9 -tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Navarro, M.; **Fernández-Ruiz, J.J.**; de Miguel, R.; Hernández, M.L.; Cebeira, M.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 45 : 291-298 (1993).
53. Δ^9 -Tetrahydrocannabinol affects mesolimbic dopaminergic activity in the female rat brain: interactions with estrogens. Bonnin, A.; **Fernández-Ruiz, J.J.**; Martín, M.; Rodríguez de Fonseca, F.; Hernández, M.L.; Ramos, J.A. Journal of Neural Transmission 92 : 81-95 (1993).
54. An acute dose of Δ^9 -tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Navarro, M.; **Fernández-Ruiz, J.J.**; de Miguel, R.; Hernández, M.L.; Cebeira, M.; Ramos, J.A. Behavioral Brain Research 57 : 37-46 (1993).
55. Acute effects of Δ^9 -tetrahydrocannabinol on the tuberoinfundibular dopaminergic activity, the anterior pituitary sensitivity to dopamine and the prolactin release vary as a function of estrous cycle. Bonnin, A.; Ramos, J.A.; Rodríguez de Fonseca, F.; Cebeira, M.; **Fernández-Ruiz, J.J.** Neuroendocrinology 58 : 280-286 (1993).
56. Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids. Navarro, M.; Rodríguez de Fonseca, F.; Hernández, M.L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Pharmacology, Biochemistry and Behavior 47 : 47-58 (1994).
57. Down-regulation of rat brain cannabinoid binding sites after chronic Δ^9 -tetrahydrocannabinol treatment. Rodríguez de Fonseca, F.; Gorriti, M.A.; **Fernández-Ruiz, J.J.**; Palomo, T.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 47 : 33-40 (1994).
58. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Rodríguez de Fonseca, F.; Cebeira, M.; Ramos, J.A.; Martín, M.; **Fernández-Ruiz, J.J.** Life Sciences 54 : 159-170 (1994).
59. Modifications of mesolimbic and nigrostriatal dopaminergic activities after intracerebroventricular administration of prolactin. Hernández, M.L.; **Fernández-Ruiz, J.J.**; Navarro, M.; de Miguel, R.; Cebeira, M.; Vaticón, D.; Ramos, J.A. Journal of Neural Transmission 96 : 63-79 (1994).
60. The putative cannabinoid receptor ligand, anandamide, stimulates hypothalamic tyrosine hydroxylase activity and inhibits prolactin release. Romero, J.; García, L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Neuroendocrinology Letters 16 : 159-164 (1994).
61. Possible role of the cytochrome P450-linked monooxygenase system in preventing Δ^9 -tetrahydrocannabinol-induced stimulation of tuberoinfundibular dopaminergic activity in female rats. Bonnin, A.; de Miguel, R.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Ramos, J.A. Biochemical Pharmacology 48 : 1387-1392 (1994).
62. Changes in tyrosine hydroxylase gene expression in mesencephalic catecholaminergic neurons of immature and adult male rats perinatally exposed to cannabinoids. Bonnin, A.; de Miguel, R.; Rodríguez-Manzaneque, J.C.; **Fernández-Ruiz, J.J.**; Santos, A.; Ramos, J.A. Developmental Brain

Research 81 : 147-150 (1994).

63. Effects of Δ^9 -tetrahydrocannabinol on tuberoinfundibular dopaminergic activity and prolactin release in estrogen-replaced ovariectomized rats. Bonnín, A.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Ramos, J.A. Neuroendocrinology Letters 16 : 305-314 (1994).
64. Effects of catecholamine synthesis inhibitors and adrenergic receptor antagonists on restraint-induced LH release. Martín, A.I.; **Fernández-Ruiz, J.J.**; López-Calderón, A. Journal of Endocrinology 144 : 511-515 (1995).
65. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Romero, J.; García, L.; Cebeira, M.; Zdrozny, D.; **Fernández-Ruiz, J.J.**; Ramos, J.A. Life Sciences 56 : 2033-2040 (1995).
66. The prenatal exposure to Δ^9 -tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development. Bonnín, A.; de Miguel, R.; Hernández, M.L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Life Sciences 56 : 2177-2184 (1995).
67. Perinatal exposure to Δ^9 -tetrahydrocannabinol (Δ^9 -THC) leads to changes in opioid-related behavioral patterns in rats. Vela, G.; Fuentes, J.A.; Bonnín, A.; **Fernández-Ruiz, J.J.**; Ruiz-Gayo, M. Brain Research 680 : 142-147 (1995).
68. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Δ^9 -tetrahydrocannabinol. Romero, J.; García, L.; **Fernández-Ruiz, J.J.**; Cebeira, M.; Ramos, J.A. Pharmacology, Biochemistry & Behavior 51 : 731-737 (1995).
69. Effects of anandamide on hepatic fatty acid metabolism. Guzmán, M.; **Fernández-Ruiz, J.J.**; Sánchez, C.; Velasco, G.; Ramos, J.A. Biochemical Pharmacology 50 : 885-888 (1995).
70. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Romero, J.; de Miguel, R.; García-Palomero, E.; **Fernández-Ruiz, J.J.**; Ramos, J.A. Brain Research 694 : 223-232 (1995).
71. Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats. Navarro M, de Miguel R, Rodríguez de Fonseca F, Ramos JA, **Fernández-Ruiz JJ** Behavioral Brain Research 75 : 91-98 (1996).
72. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Romero J, García-Palomero E, Lin SY, Ramos JA, Makriyannis A, **Fernández-Ruiz JJ** Life Sciences 58 : 1249-1257 (1996).
73. Involvement of GABA B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Romero J, García-Palomero E, **Fernández-Ruiz JJ**, Ramos JA Behavioral Pharmacology 7 : 299-302 (1996).
74. Perinatal Δ^9 -tetrahydrocannabinol exposure in rats modifies the responsiveness of midbrain dopaminergic neurons in adulthood to a variety of challenges with dopaminergic drugs. García-Gil L, de Miguel R, Ramos JA, **Fernández-Ruiz JJ** Drug and Alcohol Dependence 42 : 155-166 (1996).
75. Effect of perinatal exposure to Δ^9 -tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. Bonnín, A.; de Miguel, R.; Castro, J.G.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Journal of Molecular Neuroscience 7 : 291-308 (1996).
76. Atypical location of cannabinoid receptors in white matter areas during rat brain development. Romero J, García-Palomero E, Berrendero F, García-Gil L, Hernández ML, Ramos JA, **Fernández-Ruiz JJ**. Synapse 26 : 317-323 (1997).
77. Δ^9 -Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. Hernández ML, García-Gil L, Berrendero F, Ramos JA, **Fernández-Ruiz JJ**. Journal of Molecular Neuroscience 8 : 83-91 (1997).
78. Effect of chronic exposure to Δ^9 -tetrahydrocannabinol on cannabinoid receptor binding and mRNA

- levels in several rat brain regions. Romero, J.; García-Palomero, E.; Castro, J.G.; García-Gil, L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Molecular Brain Research 46 : 100-108 (1997).
79. Time-course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. **Fernández-Ruiz, J.J.**; Muñoz, R.M.; Romero, J.; Villanua, M.A.; Makriyannis, A.; Ramos, J.A. Biochemical Pharmacology 53 : 1919-1927 (1997).
80. Perinatal Δ^9 -tetrahydrocannabinoid exposure alters the responsiveness of hypothalamic dopaminergic neurons to dopamine-acting drugs in adult rats. García-Gil, L.; de Miguel, R.; Muñoz, R.M.; Cebeira, M.; Villanua, M.A.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Neurotoxicology and Teratology 19 : 477-487 (1997).
81. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Romero, J.; de Miguel, R.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Life Sciences 62 : 351-363 (1998).
82. Loss of cannabinoid receptor binding and mRNA levels and cannabinoid agonist-stimulated [35 S]GTP γ S binding in the basal ganglia of aged rats. Romero, J.; Berrendero, F.; García-Gil, L.; de la Cruz, P.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Neuroscience 84 : 1075-1083 (1998).
83. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Manzanares, J.; Corchero, J.; Romero, J.; **Fernández-Ruiz, J.J.**; Ramos, J.A.; Fuentes, J.A. Molecular Brain Research 55 : 126-132 (1998).
84. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35 S]GTP γ S binding in morphine-dependent mice. Romero, J.; **Fernandez-Ruiz, J.J.**; Vela, G.; Fuentes, J.A.; Ramos, J.A. Drug and Alcohol Dependence 50 : 241-249 (1998).
85. Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Romero, J.; Wenger, T.; de Miguel, R.; Ramos, J.A.; **Fernandez-Ruiz, J.J.** Life Sciences 63 : 351-356 (1998).
86. Perinatal Δ^9 -tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. Corchero, J.; García-Gil, L.; Manzanares, J.; **Fernandez-Ruiz, J.J.**; Fuentes, J.A.; Ramos, J.A. Life Sciences 63 : 843-850 (1998).
87. Perinatal Δ^9 -tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats. García-Gil, L.; Ramos, J.A.; Rubino, T.; Parolaro, D.; **Fernández-Ruiz, J.J.** Neurotoxicology and Teratology 20 : 549-553 (1998).
88. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Berrendero, F.; Garcia-Gil, L.; Hernandez, M.L.; Romero, J.; Cebeira, M.; de Miguel, R.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Development 125 : 3179-3188. (1998).
89. Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic γ -aminobutyric acid (GABA) inputs. de Miguel, R.; Romero, J.; Muñoz, R.; Garcia-Gil, L.; Gonzalez, S.; Villanua, M.A.; Makriyannis, A.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Biochemical Pharmacology 56 : 1331-1338 (1998).
90. Maternal exposure to Δ^9 -tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central μ -opioid receptors in adult offspring female rats. Vela, G.; Martín, S.; García-Gil, L.; Crespo, J.A.; Ruiz-Gayo, M.; **Fernández-Ruiz, J.J.**; García-Lecumberri, C.; Pélaprat, D.; Fuentes, J.A.; Ramos, J.A.; Ambrosio, E. Brain Research 807 : 101-109 (1998).
91. Exposure to psychoactive compounds of marihuana during perinatal development alters the responsiveness of midbrain dopaminergic neurons in adulthood to drugs which deplete dopamine stores and induce tyrosine hydroxylase gene expression. García-Gil L, Castro JG, Bonnin A, de Miguel R, Ramos JA, **Fernández-Ruiz JJ.** Arquivos de Medicina 12 (supl. 1) 141-146 (1998).
92. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated

- exposure to Δ^9 -tetrahydrocannabinol . Romero, J.; Berrendero, F.; Manzanares, J.; Pérez, A.; Corchero, J.; Fuentes, J.A.; **Fernández-Ruiz, J.J.** Ramos, J.A. Synapse 30 : 298-308 (1998).
93. Cannabinoid receptor and WIN-55,212-2-stimulated [³⁵S]GTP γ S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to Δ^9 -tetrahydrocannabinol. Romero, J.; Berrendero, F.; Garcia, L.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Journal of Molecular Neuroscience 11 : 109-119 (1998).
94. Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Berrendero, F.; Romero, J.; Garcia-Gil, L.; Suarez, I.; de la Cruz, P.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Biochimica et Biophysica Acta 1407 : 205-214 (1998).
95. Cannabinoid receptor binding and WIN-55, 212-2-stimulated [³⁵S]GTP γ S binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Romero, J.; Berrendero, F.; Garcia, L.; Lin, S.Y.; Makriyannis, A.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Neurochemistry International 34 : 473-482 (1999).
96. Perinatal Δ^9 -tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA_B, but not by GABA_A receptors agonist in adult rats. García, L.; de Miguel, R.; Romero, J.; Perez, A.; Ramos, J.A.; **Fernandez-Ruiz, J.J.** Neurotoxicology and Teratology 21 : 277-283 (1999).
97. Time-dependent differences of repeated administration with Δ^9 -tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by μ -opioid and CB1-cannabinoid receptors in the caudate-putamen. Corchero, J.; Romero, J.; Berrendero, F.; **Fernández-Ruiz, J.J.**; Ramos, J.A.; Fuentes, J.A.; Manzanares, J. Molecular Brain Research 67 : 148-157 (1999).
98. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, **Fernández-Ruiz JJ**, Di Marzo V, Biochemical and Biophysical Research Communications 256 : 377-380 (1999).
99. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Berrendero F, Sepe N, Ramos JA, Di Marzo V, **Fernández-Ruiz JJ** Synapse 33 : 181-191 (1999).
100. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. González S, Romero J, de Miguel R, Lastres-Becker I, Villanua MA, Makriyannis A, Ramos JA, **Fernández-Ruiz JJ**, Life Sciences 65 : 327-336 (1999).
101. Identification of endocannabinoids and cannabinoid CB₁ receptor mRNA in the pituitary gland. González S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T, Romero J, Fuentes JA, Di Marzo V, Ramos JA, **Fernández-Ruiz JJ**. Neuroendocrinology 70 : 137-145 (1999).
102. Immunocytochemical demonstration of CB₁ cannabinoid receptors in the anterior lobe of the pituitary gland. Wenger T, **Fernández-Ruiz JJ**, Ramos JA. Journal of Neuroendocrinology 11 : 873-878 (1999).
103. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to Δ^9 -tetrahydrocannabinol. Garcia-Gil, L.; Romero, J.; Ramos, J.A.; **Fernández-Ruiz, J.J.** Drug and Alcohol Dependence 55 : 127-136 (1999).
104. Neuronal and astroglial response to pre- and perinatal exposure to Δ^9 -tetrahydrocannabinol in the rat substantia nigra. Suarez I, Bodega G, Ramos JA, **Fernández-Ruiz JJ**, Fernandez B. Developmental Neuroscience 22 : 253-263 (2000).
105. Neonatal methamphetamine in the rat: evidence for gender-specific differences upon tyrosine hydroxylase enzyme in the dopaminergic nigrostriatal system. Gomes-da-Silva J, Perez-Rosado A, de Miguel R, **Fernández-Ruiz J**, Silva MC, Tavares MA. Annals of the New York Academy of Sciences 914 : 431-438 (2000).
106. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ^9 -tetrahydrocannabinol-tolerant rats. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, **Fernández-Ruiz JJ**. Journal of Neurochemistry 74 : 1627-1635 (2000).

107. Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Gonzalez S, Bisogno T, Wenger T, Manzanares J, Milone A, Berrendero F, Di Marzo V, Ramos JA, **Fernández-Ruiz JJ**. Biochemical and Biophysical Research Communications 270 : 260-266 (2000).
108. Activational role of cannabinoids on movement. Sañudo-Peña MC, Romero J, Seale GE, **Fernández-Ruiz JJ**, Walker JM. European Journal of Pharmacology 391 : 269-274 (2000).
109. Prenatal Δ^9 -tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. Perez-Rosado A, Manzanares J, **Fernández-Ruiz J**, Ramos JA. Developmental Brain Research 120 : 77-81 (2000).
110. Unilateral 6-hydroxidopamine lesions of nigrostriatal dopaminergic neurons increased CB₁ receptor mRNA levels in the caudate-putamen. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, **Fernández-Ruiz JJ**, de Yébenes JG, Ramos JA. Life Sciences 66 : 485-494 (2000).
111. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Hernandez ML, Berrendero F, Suarez I, Garcia-Gil L, Cebeira M, Mackie K, Ramos JA, **Fernández-Ruiz J**. Brain Research 857 : 56-65 (2000).
112. Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Gonzalez S, Mauriello-Romanazzi G, Berrendero F, Ramos JA, Franzoni MF, **Fernández-Ruiz J**. Pituitary 3 : 221-226 (2000).
113. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Niederhoffer N, Hansen HH, **Fernández-Ruiz JJ**, Szabo B. British Journal of Pharmacology 134 : 1319-1327 (2001).
114. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, **Fernández-Ruiz JJ**, Hansen HS. Journal of Neurochemistry 78 : 1415-1427 (2001).
115. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, **Fernández-Ruiz JJ**. European Journal of Neuroscience 14 : 1827-1832 (2001).
116. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Lastres-Becker I, Fezza F, Cebeira M, Bisogno T, Ramos JA, Milone A, **Fernández-Ruiz J**, Di Marzo V. Neuroreport 12 : 2125-2129 (2001).
117. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, **Fernández-Ruiz JJ**. European Journal of Pharmacology 420 : 123-131 (2001).
118. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Berrendero F, Sanchez A, Cabranes A, Puerta C, Ramos JA, Garcia-Merino A, **Fernández-Ruiz J**. Synapse 41 : 195-202 (2001).
119. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. López-Rodríguez ML, Viso A, Ortega-Gutierrez S, Lastres-Becker I, Gonzalez S, **Fernández-Ruiz J**, Ramos JA. Journal of Medicinal Chemistry 44 : 4505-4508 (2001).
120. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Gonzalez S, Grazia Cascio M, **Fernández-Ruiz J**, Fezza F, Di Marzo V, Ramos JA. Brain Research 954 : 73-79 (2002).
121. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. de Lago E, **Fernández-Ruiz J**, Ortega-Gutierrez S, Viso A, Lopez-Rodríguez ML, Ramos JA. European Journal of Pharmacology 449 : 99-103 (2002).

122. Prenatal exposure to methamphetamine in the rat. Ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons. Gomes-da-Silva J, Perez-Rosado A, de Miguel R, **Fernández-Ruiz J**, Silva MC, Tavares MA. Annals of the New York Academy of Sciences 965 : 68-77 (2002).
123. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. Hansen HH, Azcoitia I, Pons S, Romero J, Garcia-Segura LM, Ramos JA, Hansen HS, **Fernández-Ruiz J**. Journal of Neurochemistry 82 : 154-158 (2002).
124. The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Wenger T, Gerendai I, Fezza F, Gonzalez S, Bisogno T, **Fernández-Ruiz J**, Di Marzo V. Life Sciences 70 : 1407-1414 (2002).
125. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Lastres-Becker I, Berrendero F, Lucas JJ, Martin-Aparicio E, Yamamoto A, Ramos JA, **Fernández-Ruiz JJ**. Brain Research 929 : 236-242 (2002).
126. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ^9 -tetrahydrocannabinol. Perez-Rosado A, Gomez M, Manzanares J, Ramos JA, **Fernández-Ruiz J**. Neurotoxicity Research 4 : 211-218 (2002).
127. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Lastres-Becker I, Gómez M, De Miguel R, Ramos JA, **Fernández-Ruiz J**. Neurotoxicity Research 4 : 601-608 (2002).
128. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB1 receptor binding and mRNA levels. González S, **Fernández-Ruiz J**, Sparpaglione V, Parolaro D, Ramos JA. Drug and Alcohol Dependence 66 : 77-84 (2002).
129. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J, Ramos JA, **Fernández-Ruiz J**. Synapse 44 : 23-35 (2002).
130. Reduced Glial Fibrillary Acidic Protein and Glutamine Synthetase Expression in Astrocytes and Bergmann Glial Cells in the Rat Cerebellum Caused by Δ^9 -Tetrahydrocannabinol Administration during Development. Suarez I, Bodega G, **Fernández-Ruiz JJ**, Ramos JA, Rubio M, Fernandez B. Developmental Neuroscience 24 : 300-312 (2002).
131. Effects of perinatal exposure to Δ^9 -tetrahydrocannabinol on operant morphine-reinforced behavior. Gonzalez B, de Miguel R, Martin S, Perez-Rosado A, Romero J, Garcia-Lecumberri C, **Fernández-Ruiz J**, Ramos JA, Ambrosio E. Pharmacology, Biochemistry and Behavior 75 : 577-584 (2003).
132. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E, **Fernández-Ruiz J**. Neuroreport 14 : 813-816 (2003).
133. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. González S, Schmid PC, **Fernández-Ruiz J**, Krebsbach R, Schmid HH, Ramos JA. Addiction Biology 8 : 159-166 (2003).
134. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, de Lago E, **Fernández-Ruiz J**, Ramos JA. Journal of Medicinal Chemistry 46 : 1512-1522 (2003).
135. Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain. Gómez M, Hernandez M, Johansson B, de Miguel R, Ramos JA, **Fernández-Ruiz J**. Developmental Brain Research 147 : 201-207 (2003).
136. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, de Lago E, **Fernández-Ruiz J**, Ramos JA. European Journal of Medicinal Chemistry 38 : 403-412 (2003).

137. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, **Fernández-Ruiz JJ**. Journal of Neurochemistry 84 : 1097-1109 (2003).
138. Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal Δ^9 -tetrahydrocannabinol exposure. Suárez I, Bodega G, **Fernández-Ruiz J**, Ramos JA, Rubio M, Fernández B. Cerebellum 3 : 66-74 (2004).
139. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. González S, Valenti M, de Miguel R, Fezza F, **Fernández-Ruiz J**, Di Marzo V, Ramos JA. British Journal of Pharmacology 143 : 455-464 (2004).
140. Behavioral and molecular changes elicited by acute administration of SR141716 to Δ^9 -tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. González S, **Fernández-Ruiz J**, Di Marzo V, Hernández M, Arevalo C, Nicanor C, Cascio MG, Ambrosio E, Ramos JA. Drug and Alcohol Dependence 74 : 159-170 (2004).
141. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, **Fernández-Ruiz J**. Brain Research 1007 : 152-159 (2004).
142. Transthyretin is involved in depression-like behaviour and exploratory activity. Sousa JC, Grandela C, **Fernández-Ruiz J**, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA. Journal of Neurochemistry 88 : 1052-1058 (2004).
143. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D, **Fernández-Ruiz J**, Di Marzo V. European Journal of Pharmacology 484 : 249-257 (2004).
144. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, **Fernández-Ruiz J**, Brouillet E. Neuroreport 15 : 2375-2379 (2004).
145. Effects of neonatal exposure to metamphetamine. Catecholamine levels in brain areas of the developing brain. Gomez da Silva J, de Miguel R, **Fernández-Ruiz J**, Summavielle T, Tavares MA. Annals of the New York Academy of Sciences 1025 : 602-611 (2004).
146. Prenatal cannabinoid exposure down-regulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum. Suárez I, Bodega G, Rubio M, **Fernandez-Ruiz J**, Ramos JA, Fernandez B. Developmental Neuroscience 26 : 45-53 (2004).
147. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity *in vivo* and *in vitro*: relevance to Parkinson's disease. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, **Fernández-Ruiz J**. Neurobiology of Disease 19 : 96-107 (2005).
148. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. González S, Mena MA, Lastres-Becker I, Serrano A, de Yébenes JG, Ramos JA, **Fernández-Ruiz J**. Brain Research 1046 : 195-206 (2005).
149. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. de Lago E, Urbani P, Ramos JA, Di Marzo V, **Fernández-Ruiz J**. Brain Research 1050 : 210-216 (2005).
150. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. de Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, **Fernández-Ruiz J**, Di Marzo V. Biochemical Pharmacology 70 : 446-452 (2005).
151. Decreased endocannabinoid levels in the brain and beneficial agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, **Fernández-Ruiz J**. Neurobiology of Disease 20 : 207-217 (2005).
152. Chronic Δ^9 -tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.

- Sagredo O, Ramos JA, **Fernández-Ruiz J**, Rodríguez ML, de Miguel R. Archives of Pharmacology 372 : 313-317 (2006)
153. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. de Lago E, **Fernández-Ruiz J**, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, López-Rodríguez M, Ramos JA. European Neuropsychopharmacology 16 : 7-18 (2006).
 154. Effects of rimonabant, a selective cannabinoid CB₁ receptor antagonist, in a rat model of Parkinson's disease. González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, **Fernández-Ruiz J**. Brain Research 1073-1074 : 209-219 (2006)
 155. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Cabranes A, Pryce G, Baker D, **Fernández-Ruiz J**. Brain Research . 1107 : 199-205 (2006).
 156. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. De Lago E, Gustafsson SB, **Fernández-Ruiz J**, Nilsson J, Jacobsson SO, Fowler CJ. Journal of Neurochemistry 99 : 677-688 (2006).
 157. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Rojo AI, Montero C, Salazar M, Close RM, **Fernández-Ruiz J**, Sánchez-González MA, de Sagarra MR, Jackson-Lewis V, Cavada C, Cuadrado A. European Journal of Neuroscience 24 : 1874-1884 (2006).
 158. Effects of inhibition of fatty acid amide hydrolase vs the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB1 receptors. Millns PJ, Chimenti M, Ali N, Ryland E, de Lago E, **Fernández-Ruiz J**, Chapman V, Kendall DA. European Journal of Neuroscience 24 : 3489-3495 (2006).
 159. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions. de Lago E, Ortega-Gutiérrez S, Ramos JA, López Rodríguez ML, **Fernández-Ruiz J**. Life Sciences 80 : 979-988 (2007).
 160. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, **Fernández-Ruiz J**. Brain Research 1134 : 162-170 (2007).
 161. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Rubio M, McHugh D, **Fernández-Ruiz J**, Bradshaw H, Walker JM. Neuroscience Letters 421: 270-274 (2007).
 162. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain. Gómez M, Hernández M, **Fernández-Ruiz J**. Brain Research 1145 : 48-55 (2007).
 163. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Sagredo O, Ramos JA, Decio A, Mechoulam R, **Fernández-Ruiz J**. European Journal of Neuroscience 26 : 843-851 (2007).
 164. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: evidence for a role of these receptors in axonal growth and guidance. Gómez M, Hernández ML, Pazos MR, Tolón RM, Romero J, **Fernández-Ruiz J**. Neuroscience 153 : 687-699 (2008).
 165. Cannabinoid CB1 Receptors Are Expressed by Parietal Cells of the Human Gastric Mucosa. Pazos MR, Tolón RM, Benito C, Rodríguez CF, Gorgojo JJ, Nevado M, Alvarez M, Arias F, Almodóvar F, Fernández MT, Lledó JL, González S, **Fernández-Ruiz J**, Romero J. Journal of Histochemistry & Cytochemistry 56 : 511-516 (2008).
 166. CB₁ receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Rubio M, **Fernández-Ruiz J**, de Miguel R,

- Maestro B, Walker JM, Ramos JA. Neuropharmacology 54 : 976-988 (2008).
167. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. García-Arencibia M, Ferraro L, Tanganelli S, **Fernández-Ruiz J**. Neuroscience Letters 438 : 10-13 (2008).
168. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas. Rubio M, de Miguel R, **Fernández-Ruiz J**, Gutiérrez-López D, Carai MA, Ramos JA. Drug and Alcohol Dependence 99 : 354-358 (2009).
169. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, **Fernández-Ruiz J**. Glia 57, 1154-1167 (2009)
170. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H, Becker D, Voos W, Leuner K, Müller W, Kudin A, Kunz W, Zimmermann A, Roper J, Wenzel D, Jendrach M, García-Arencibia M, **Fernández-Ruiz J**, Huber L, Rohrer H, Barrera M, Reichert A, Rüb U, Chen A, Nussbaum R, Auburger G. PLOS One 4, e 5777 (2009)
171. Cannabinoid CB1 receptors are early down-regulated followed by a further up-regulation in the basal ganglia of mice with deletion of specific park genes. García-Arencibia M, García C, Kurz A, Rodríguez-Navarro JA, Gispert-Sánchez S, Mena MA, Auburger G, García de Yébenes J, **Fernández-Ruiz J**. Journal of Neural Transmission Supplementum 73, 269-275 (2009)
172. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, **Fernández-Ruiz J**, Guzmán M, Galve-Roperh I. Brain 132, 3152-3164 (2009).
173. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Castillo A, Tolón MR, **Fernández-Ruiz J**, Romero J, Martínez-Orgado J. Neurobiology of Disease 37, 434-440 (2010).
174. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. Sagar D, Jhaveri M, Richardson D, Gray R, de Lago E, **Fernández-Ruiz J**, Barrett D, Kendall D, Chapman V. European Journal of Neuroscience 31, 1414-1422 (2010).
175. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. Innamorato NG, Jazwa A, Rojo AI, García C, **Fernández-Ruiz J**, Grochot-Przeczek, A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A. PLoS One 5, e11838 (2010).
176. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, **Fernández-Ruiz J**, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S. PLoS One 5, e11464 (2010).
177. Synthesis and pharmacological evaluation of new (E)- and (Z)-3-aryl-4-styryl-1H-pyrazoles as potential cannabinoid ligands. Silva VLM, Silva AMS, Pinto DCG, Rodríguez-Valsero P, Gómez M, Jagerovic N, Callado LF, Cavaleiro JAS, Elguero J, **Fernández-Ruiz J**. Arkivoc X, 223-247 (2010).
178. Loss of striatal cannabinoid receptors is a key pathogenic factor in Huntington's disease. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Díez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, García de Yébenes J, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, **Fernández-Ruiz J**, Galve-Roperh I, Guzmán M. Brain 134, 119-136 (2011).
179. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ^9 -THCV in animal models of Parkinson's disease. García C, Palomo-Garo C, García-Arencibia M, Ramos JA, Pertwee R, **Fernández-Ruiz J**. British Journal of Pharmacology 163, 1495-1506 (2011).
180. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease

- modifying therapy for experimental Parkinsonism. Jazwa A, Rojo AI, Innamorato NG, Hesse M, **Fernández-Ruiz J**, Cuadrado A. Antioxidants & Redox Signaling 14, 2347-2360 (2011).
181. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, **Fernández-Ruiz J**. Journal of Neuroscience Research 89, 1509-1518 (2011).
182. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. Rubio M, Villain H, Docagne F, Benoit DR, Ramos JA, Vivien D, **Fernández-Ruiz J**, Ali C. Plos One 6, e23690 (2011)
183. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Moreno-Martet M, Mestre L, Loria F, Guaza C, **Fernández-Ruiz J**, de Lago E. Neuroscience Letters 508, 67-72 (2012)
184. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: Role of CB1 and CB2 receptors. Valdeolivas S, Satta V, Pertwee RG, **Fernández-Ruiz J**, Sagredo O. ACS Chemical Neuroscience 3, 400-406 (2012)
185. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, **Fernández-Ruiz J**. Neuropharmacology 62, 2299-2308 (2012)
186. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DCG, Goya P, Reggio P, Martín MI, **Fernández-Ruiz J**, Silva AMS, Jagerovic N. ChemMedChem 7, 452-463 (2012)
187. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, **Fernández-Ruiz J**, Martínez-Orgado J. Neuropharmacology 63, 776-783 (2012)
188. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. González-Granja A, Carrillo Salinas F, Pagani A, Gómez-Cañas M, Negui R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Calzado MA, Bellido ML, **Fernández-Ruiz J**, Appendino G, Guaza C, Muñoz E. Journal of Neuroimmune Pharmacology 7, 1002-1016 (2012)
189. Design and synthesis of novel cannabinoid ligands based on a 1,2,3-triazole scaffold. Szafranska P, Dyducha K, Kosciolka T, Wróbel T, Gómez-Cañas M, Gómez-Ruiz M, **Fernández-Ruiz J**, Mlynarski J. Letters in Drug Design & Discovery 10, 169-172 (2013)
190. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and LH21. Alvarado M, Decara J, Luque MJ, Hernández-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, **Fernández-Ruiz J**, Elguero J, Jagerovic N, Serrano A, Goya P, Rodríguez de Fonseca F. Bioorganic & Medicinal Chemistry 21, 1708-1716 (2013)
191. Description of a bivalent cannabinoid ligand with hypophagic properties. Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruiz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, **Fernández-Ruiz J**, Meana JJ, Jagerovic N. Archiv der Pharmazie 346, 171-179 (2013)
192. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. Casarejos MJ, Perucho J, Gómez A, Muñoz MP, Fernández-Estévez M, Sagredo O, **Fernández-Ruiz J**, Guzmán M, García de Yébenes J, Mena MA. Journal of Alzheimer's Disease 35, 525-539 (2013)
193. Neuroprotective properties of standardized extracts of *Hypericum perforatum* on rotenone model of Parkinson's disease. Gómez del Rio MA, Sánchez-Reus MI, Iglesias I, Pozo MA, García-Arencibia M, **Fernández-Ruiz J**, García-García L, Delgado M, Benedí J. CNS Neurological Disorders and Drug Targets 12, 665-679 (2013)
194. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Pryce G, Cabranes A, **Fernández-Ruiz J**, Bisogno T, Di Marzo

- V, Long L, Cravatt B, Giovannoni G, Baker D. Multiple Sclerosis Journal 19, 1896-1904 (2013)
195. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT_{1A} receptors. Espejo-Porras F, **Fernández-Ruiz J**, Pertwee RG, Mechoulam R, García MC. Neuropharmacology 75C, 155-163 (2013)
196. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: potential role of ciclooxigenase-2-dependent metabolism of 2-AG. Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti F, Allara M, Sagredo O, di Marzo V, **Fernández-Ruiz J**. Cell Death & Disease 4, e862 (2013)
197. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Morales P, Vara D, Gómez-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, **Fernández-Ruiz J**, Díaz-Laviada I, Jagerovic N. European Journal of Medicinal Chemistry 70C, 111-119 (2013)
198. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. González-Naranjo P, Pérez N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez E, Martín MI, Gómez-Cañas M, García-Arencibia M, **Fernández-Ruiz J**, Páez JA. European Journal of Medicinal Chemistry 73, 56-72 (2014)
199. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, Rodríguez de Fonseca F, **Fernández-Ruiz J**, Goya P, Meana JJ, Martín MI, Jagerovic N. Drug Design, Development & Therapy 8, 263-277 (2014)
200. Changes in CB₁ and CB₂ receptors in the *postmortem* cerebellum of humans affected by spinocerebellar ataxias. Rodríguez-Cueto C, Benito C, **Fernández-Ruiz J**, Romero J, Hernández ML, Gómez-Ruiz M. British Journal of Pharmacology 171, 1472-1489 (2014)
201. Endocannabinoid hydrolyzing enzymes in the *postmortem* cerebellum of humans affected by hereditary autosomal dominant ataxias. Rodríguez-Cueto C, Benito C, Romero J, Hernández ML, Gómez-Ruiz M, **Fernández-Ruiz J**. Pathobiology 81, 149-159 (2014)
202. A restricted population of CB₁ cannabinoid receptors with neuroprotective activity. Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, **Fernández-Ruiz J**, Galve-Roperh I, Guzmán M. Proceedings of the National Academy of Sciences of the United States of America 111, 8257-8262 (2014)
203. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1G93A transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. Moreno-Martet M, Espejo-Porras F, **Fernández-Ruiz J**, de Lago E. CNS Neuroscience & Therapeutics 20, 809-815 (2014).
204. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Ooms M, Rietjens R, Rangarajan J, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, **Fernández-Ruiz J**, Bormans G, Van Laere K, Casteels C. Neurobiology of Aging 35, 2858-2869 (2014)
205. Targeting CB₂-GPR55 receptor heteromers modulates cancer cell signaling. Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, Canela EI, **Fernández-Ruiz J**, Guzmán M, McCormick PJ, Sánchez C. Journal of Biological Chemistry 289, 21960-21972 (2014).
206. Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. García MC, Cinquna V, Palomo-Garo C, Rábano A, **Fernández-Ruiz J**. Neuroscience Letters 587, 1-4 (2015)
207. The endocannabinoid system is altered in the postmortem prefrontal cortex of alcoholic subjects. Erdozain A, Rubio M, Valdizán EM, Pazos A, Meana JJ, **Fernández-Ruiz J**, Alexander S, Callado LF, Addiction Biology 20, 773-783 (2015)
208. Selective, nontoxic CB₂ cannabinoid o-quinone with in vivo activity against triple negative breast cancer. Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores J, Goya P, **Fernández-Ruiz J**, Sánchez C, Jagerovic N. Journal of Medicinal Chemistry 58, 2256-64 (2015)

209. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TPP-43-related disorders. Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, di Marzo V, de Lago E, **Fernández-Ruiz J**. Journal of Neuroimmune Pharmacology 10, 233-244 (2015)
210. A Sativex-like combination of phytocannabinoids as disease-modifying therapy in a viral model of multiple sclerosis. Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, **Fernández-Ruiz J**, Guaza C. British Journal of Pharmacology 172, 3579-3595 (2015)
211. Altered CB₁ receptor coupling to G-proteins in the postmortem caudate nucleus and cerebellum of alcoholic subjects. Erdozain A, Rubio M, **Fernández-Ruiz J**, Meana JJ, Callado LF. Journal of Psychopharmacology 29, 1137-1145 (2015)
212. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB₂ receptor antagonists. Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos MR, Pinna GA, **Fernández-Ruiz J**, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G. European Journal of Medicinal Chemistry 101, 651-667 (2015)
213. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to delta-9-tetrahydrocannabinol acting through CB₁ receptors. Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, **Fernández-Ruiz J**, Guaza C, de Lago E. Multiple Sclerosis and Related Disorders 4, 505-511 (2015)
214. Potential of the cannabinoid CB₂ receptor as a pharmacological target against inflammation in Parkinson's disease. Gómez-Gálvez Y, Palomo-Garo C, **Fernández-Ruiz J**, García MC. Progress in Neuro-Psychopharmacology & Biological Psychiatry 64, 200-208 (2016)
215. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, **Fernández-Ruiz J**. Pharmacology Research & Perspectives 4, e00220 (2016)
216. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor- γ and CB₂ pathways. Del Río C, Navarrete C, Collado JA, Bellido M, Gomez-Cañas M, Pazos MR, **Fernandez-Ruiz J**, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. Scientific Reports 6, 21703 (2016)
217. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB₂ receptor ligands with antagonist/inverse agonist properties. Deiana V, Gómez-Cañas M, Pazos MR, **Fernández-Ruiz J**, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA. European Journal of Medicinal Chemistry 112, 66-80 (2016)
218. Identification of novel GPR55 modulators using cell-impedance-based label-free technology. Morales P, Whyte L, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, **Fernández-Ruiz J**, Ross RA, Jagerovic N. Journal of Medicinal Chemistry 59, 1840-1853 (2016)
219. Biological characterization of PM226, a chromenoisoxazole, as a selective CB₂ receptor agonist with neuroprotective profile. Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, **Fernández-Ruiz J**, García-Arencibia M, Pazos MR. Pharmacological Research 110, 205-215 (2016)
220. Targeting the cannabinoid CB₂ receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Palomo-Garo C, Gómez-Gálvez Y, García MC, **Fernández-Ruiz J**. Pharmacological Research 110, 181-192 (2016)
221. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. López-Sendón JL, García-Caldentey J, Trigo-Cubillo P, Ruiz-Romero C, García-Ribas G, Alonso-Arias A, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutiérrez S, García-Bermejo ML, **Fernández-Ruiz J**, Guzmán M, García de Yébenes Prous J. Journal of Neurology 263, 1390-1400 (2016)

222. VCE-003.2, a novel cannabigerol derivate, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Díaz-Alonso J, Paraiso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguares J, **Fernández-Ruiz J**, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E. Scientific Reports 6, 29789 (2016)
223. Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos MR, Goya P, Reggio PH, Guaza C, Franco R, **Fernández Ruiz J**, Jagerovic N. Journal of Medicinal Chemistry 59, 6753-6771 (2016).
224. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, **Fernández-Ruiz J**. Neuroscience 339, 191-209 (2016)
225. Synthesis of a novel CB₂ cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. Morales P, Moreno L, **Fernández-Ruiz J**, Jagerovic N. Journal of Porphyrins and Phthalocyanines 21, 67-76 (2017)
226. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, **Fernández-Ruiz J**, Murineddu G. European Journal of Medicinal Chemistry 127, 398-412 (2017)
227. Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington's disease. Valdeolivas S, Sagredo O, Delgado M, Pozo MA, **Fernández-Ruiz J**. International Journal of Molecular Sciences 18, E684 (2017)
228. Up-regulation of CB₂ receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates J, Pérez-Díaz C, de Lago E, **Fernández-Ruiz J**. Disease Models & Mechanisms 10, 551-558 (2017)
229. Altered striatal endocannabinoid signalling in a transgenic mouse model of spinocerebellar ataxia type-3. Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, **Fernández-Ruiz J**. PlosOne, 12 e0176521 (2017)
230. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB₁ receptor ligand antagonists. Murineddu G, Deligia F, Ragusa G, García-Toscano L, Gómez-Cañas M, Asproni B, Satta V, Cichero E, Pazos MR, Fossa P, Loriga G, **Fernández-Ruiz J**, Pinna GA. Bioorganic and Medicinal Chemistry 26, 295-307 (2018)
231. Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Espejo-Porras F, **Fernández-Ruiz J**, de Lago E. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19, 377-386 (2018)
232. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPAR γ receptor. García MC, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Bellido ML, García-Arencibia M, Pazos MR, Muñoz E, **Fernández-Ruiz J**. Journal of Neuroinflammation, 15, 19 (2018)
233. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR α -and CB₂-dependent pathways. Del Río C, Cantarero I, Palomares B, Gómez-Cañas M, **Fernández-Ruiz J**, Pavicic C, García-Martín A, Bellido ML, Ortega R, Pérez-Sánchez C, López-Pedreira C, Appendino G, Calzado M, Muñoz E. British Journal of Pharmacology 175, 3813-3831 (2018)
234. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido ML **Fernández-Ruiz J**, Muñoz E, de Lago E. Biochemical Pharmacology 157, 217-226 (2018)

235. Targeting glial CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, **Fernández-Ruiz J**. British Journal of Pharmacology 176, 1585-1600 (2019)
236. Morphine self-administration, Lewis rats, mTOR pathway, extinction, protein synthesis. Ucha M, Coria S, Núñez-Carranza A, Santos-Toscano R, Roura-Martínez D, **Fernández-Ruiz J**, Higuera-Matas A, Ambrosio E. Journal of Psychopharmacology 33, 882-893 (2019)
237. Development of an oral treatment with the PPAR- γ -acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson's disease. Burgaz S, García MC, Gómez-Cañas M, Muñoz E, **Fernández-Ruiz J**. Molecules 24, E2702 (2019)
238. Structure-effect relationships of novel semi-synthetic cannabinoid derivatives. Götz MR, Collado JA, **Fernández-Ruiz J**, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holgrave U. Frontiers in Pharmacology 10, 1284 (2019)
239. Pharmacokinetics of Sativex in dogs: Towards a potential cannabinoid-based therapy for canine disorders. Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, **Fernández-Ruiz J**. Biomolecules, 10, E279 (2020)
240. Beneficial effects of the phytocannabinoid Δ^9 -THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, **Fernández-Ruiz J**, Moratalla R. Neurobiology of Disease 141, 104892 (2020)
241. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1 δ kinase inhibitor treatment. Martínez-González L, Rodríguez-Cueto C, Cabezudo D, Bartolomé F, Andrés-Benito P, Ferrer I, Gil C, Martín-Requero Á, **Fernández-Ruiz J**, Martínez A, de Lago E. Scientific Reports 10, 4449 (2020)
242. Δ^9 -Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPAR γ and CB $_1$ receptors. Palomares B, Garrido-Rodríguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saen-Oon S, Soliva R, Collado JA, **Fernández-Ruiz J**, Morello G, Calzado MA, Appendino G, Muñoz E. British Journal of Pharmacology 177, 4034–4054 (2020)
243. Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB $_2$ Receptor. Morales P, Navarro G, Gómez-Autet M, Redondo L, **Fernández-Ruiz J**, Pérez-Benito L, Codomí A, Pardo L, Franco R, Jagerovic N. Chemistry 26, 15839-15842 (2020)
244. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice. Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, **Fernández-Ruiz J**. Mol Cell Neurosci 110, 103583 (2021)
245. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. Sánchez Montero JM, Agis-Torres A, Solano D, Söllhuber M, Fernandez M, Villaro W, Gómez-Cañas M, García-Arencibia M, **Fernández-Ruiz J**, Egea J, Martín MI, Girón R. Eur J Pharmacol 895, 173875 (2021)
246. Neuropathological characterization of a Dravet Syndrome knock-in mouse model useful for investigating cannabinoid treatments. Satta V, Alonso C, Díez P, Martín-Suárez S, Rubio M, Encinas JM, **Fernández-Ruiz J**, Sagredo O. Front Mol Neurosci 13, 602801 (2021)
247. Inactivation of the CB $_2$ receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Gómez-Almería M, García Toscano L, Romero J, Hillard CJ, de Lago E, **Fernández-Ruiz J**. Brain Pathology 31, e12972 (2021)
248. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Galán-Ganga M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, Lopez MG, Rábano A, **Fernández-Ruiz J**, Lastres-Becker I. Acta Neuropathol Commun 9, 90 (2021)
249. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB $_1$ R antagonist/CB $_2$ R agonist that prevents diabetic

- nephropathy in mice. González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, **Fernández-Ruiz J**, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E. Pharmacological Research 169, 105492 (2021)
250. Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson's disease. Burgaz S, García C, Gómez-Cañas M, Rolland A, Muñoz E, **Fernández-Ruiz J**. Molecules 26, 3245 (2021)
251. BiP heterozygosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis. Gómez-Almería M, Burgaz S, Costas-Insua C, Rodríguez-Cueto C, Santos-García I, Rodríguez-Crespo I, García C, Guzmán M, de Lago E, **Fernández-Ruiz J**. Int J Mol Sci 22, 12533 (2021)
252. Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson's disease and amyotrophic lateral sclerosis. Burgaz S, García C, Gonzalo-Consuegra C, Gómez-Almería M, Ruiz-Pino F, Unciti JD, Gómez-Cañas M, Alcalde J, Morales P, Jagerovic N, Rodríguez-Cueto C, de Lago E, Muñoz E, **Fernández-Ruiz J**. Molecules 26, 7643 (2021)
253. Preclinical investigation of β -caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome. Alonso C, Satta V, Díez-Gutiérrez P, **Fernández-Ruiz J**, Sagredo O. Neuropharmacology 205, 108914 (2022)
254. New statement about NRF2 in amyotrophic lateral sclerosis and frontotemporal dementia. Lastres-Becker I, de Lago E, Martínez A, **Fernández-Ruiz J**. Biomolecules 12, 1200 (2022)
255. Thienopyrimidine derivatives as GPR55 receptor antagonists: insight into structure-activity relationship. Figuerola-Asencio L, Morales P, Zhao P, Hurst DP, Sayed SS, Colón KL, Gómez-Cañas M, **Fernández-Ruiz J**, Croatt MP, Reggio PH, Abood ME, Jagerovic N. ACS Med Chem Lett 14, 18-25 (2022)
256. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice. Santos-García I, Rodríguez-Cueto C, Villegas P, Piscitelli F, Lauritano A, Shen CJ, Di Marzo V, **Fernández-Ruiz J**, de Lago E. J Neuroinflammation 20, 108 (2023)
257. Disease-modifying effects of cannabidiol, β -caryophyllene and their combination in Syn1-Cre/Scn1a^{WT/A1783V} mice, a preclinical model of Dravet syndrome. Alonso C, Satta V, Hernández-Fisac I, **Fernández-Ruiz J**, Sagredo O. Neuropharmacology 237, 109602 (2023)
258. The cannabigerol derivative VCE-003.2 exerts therapeutic effects in 6-hydroxydopamine-lesioned mice: comparison with the classic dopaminergic replacement therapy. Rodríguez-Carreiro S, Navarro E, Muñoz E, **Fernández-Ruiz J**. Brain Sciences 13, 1272 (2023)
259. Involvement of CB₁ and CB₂ receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice. Gonzalo-Consuegra C, Santos-García I, García-Toscano L, Martín-Baquero R, Rodríguez-Cueto C, Wittwer MB, Dzygiel P, Grether U, de Lago E, **Fernández-Ruiz J**. Biomedicine & Pharmacotherapy 174, 116473 (2024)
260. Preclinical assessment of a cannabinoid CB₂ receptor antagonist in a murine model of cerebral malaria. Borrego Escartín A, Gómez-Cañas M, Gómez-Heras SG, Marín-García P, **Fernández-Ruiz J**, Díez A. Journal of Trial and Error doi.org/10.36850/e10
261. Beneficial effect of dimethyl fumarate drug repositioning in a mouse model of TDP-43-dependent frontotemporal dementia. Silva-Llanes I, Martín-Baquero R, Berrojo-Armisen A, Rodríguez-Cueto C, **Fernández-Ruiz J**, de Lago E, Lastres-Becker I. Antioxidants 13, 1072 (2024)
262. Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy. Burgaz S, Navarro E, Rodríguez-Carreiro S, Navarrete C, Garrido-Rodríguez M, Lastres-Becker I, Chocarro J, Lanciego JL, Muñoz E, **Fernández-Ruiz J**. Behavioral and Brain Functions 20, 28 (2024)
263. Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome. Alonso C, García-Culebras A, Satta V, Hernández-Fisac I, Sierra A, Guimaré JA, Lizasoain I, **Fernández-Ruiz J**, Sagredo O. Brain, Behavior, & Immunity – Health 44, 100955 (2025)

264. Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis. García-Toscano L, Rodríguez-Cueto C, Furiano A, Hind W, de Lago E, **Fernández-Ruiz J**. Biomedicine & Pharmacotherapy 189, 118288 (2025)
265. Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (-) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives. Rodríguez-Carreiro S, Gómez-Cañas M, Lubrini F, Gonzalo-Consuegra C, Winkler M, Caprioglio D, Appendino G, García C, Morales P, Jagerovic N, Fischer JT, Fiebich BL, Goetz MR, Muñoz E, **Fernández-Ruiz J**. European Journal of Medicinal Chemistry Reports 14, 100262 (2025)
266. Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice. Gómez-Almería M, Gonzalo-Consuegra C, Rodríguez-Cueto C, Cabañas-Cotillas M, Jiménez-Amor A, Machín-Díaz I, Wittwer MB, Dzygiel P, Clemente D, Grether U, **Fernández-Ruiz J**, de Lago E. Cell Communication and Signaling 23, 427 (2025)

Review articles:

1. Perinatal exposure to marihuana or to its main psychoactive constituent, Δ^9 -tetrahydrocannabinol, affects the development of brain dopaminergic neurons. **Fernández-Ruiz JJ**, Bonnin A, de Miguel R, Castro JG, Ramos JA. Archivos de Medicina 12 (supl. 1) 67-77 (1998).
2. Role of endocannabinoids in brain development. **Fernández-Ruiz JJ**, Berrendero F, Hernández ML, Romero J, Ramos JA. Life Sciences 65: 725-736 (1999).
3. Pharmacological and biochemical interactions between opioids and cannabinoids. Manzanares J, Corchero J, Romero J, **Fernández-Ruiz JJ**, Ramos JA, Fuentes JA. Trends in Pharmacological Sciences 20: 287-294 (1999).
4. The endogenous cannabinoid system and brain development. **Fernández-Ruiz JJ**, Berrendero F, Hernández ML, Ramos JA. Trends in Neurosciences 23: 14-20 (2000).
5. Uso de los cannabinoides a través de la historia. Ramos JA, **Fernández-Ruiz J**. Adicciones 12 : 19-30 (2000).
6. Cannabinoides: Propiedades químicas y aspectos metabólicos. Ramos JA, **Fernández-Ruiz JJ**. Adicciones 12, 41-58 (2000).
7. Sistema cannabinoide endógeno: ligandos y receptores acoplados a mecanismos de transducción de señales. Ramos JA, **Fernández-Ruiz JJ**. Adicciones 12, 59-82 (2000)
8. The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, **Fernández-Ruiz J**. Pharmacology and Therapeutics 95: 137-152 (2002).
9. Endocannabinoids and basal ganglia functionality. **Fernández-Ruiz J**, Lastres-Becker I, Cabranes A, Gonzalez S, Ramos JA. Prostaglandins Leukot Essent Fatty Acids 66: 257-267 (2002).
10. Exposure to cannabinoids in the development of endogenous cannabinoid system. Ramos JA, De Miguel R, Cebeira M, Hernandez M, **Fernández-Ruiz J**. Neurotoxicity Research 4 : 363-372 (2002).
11. Endocannabinoid transporter inhibitors. López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, **Fernández-Ruiz J**, Ramos JA. Current Medicinal Chemistry – CNS Agents 2 : 129-141 (2002).
12. Cannabinoids and basal ganglia functionality. **Fernández-Ruiz J**, Lastres-Becker I, Cabranes A, de Lago E, Ramos JA. Acta Phytotherapeutica Third Series (1), 22-27 (2003).
13. The endocannabinoid system and Huntington's disease. Lastres-Becker I, De Miguel R, **Fernández-Ruiz JJ**. Current Drug Targets CNS Neurological Disorders 2 : 335-347 (2003).
14. Involvement of the endocannabinoid system in motor disorders. **Fernández-Ruiz J**, Lastres-Becker I,

- Cabranes A, de Lago E, Ramos JA. Current Medicinal Chemistry - CNS Agents 4 : 175-182 (2004).
15. Cannabinoids and gene expression during brain development. **Fernández-Ruiz J**, Gómez M, Hernandez M, de Miguel R, Ramos JA. Neurotoxicity Research 6 : 389-401 (2004).
 16. Therapeutic potential of the endocannabinoid system in the brain. Ramos JA, González S, Sagredo O, Gómez M, **Fernández-Ruiz J**. Mini-Reviews in Medicinal Chemistry 5: 609-617 (2005).
 17. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. González S, Cebeira M, **Fernández-Ruiz J**. Pharmacology, Biochemistry and Behavior 81 : 300-318 (2005).
 18. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Lastres-Becker I, **Fernández-Ruiz J**. Current Medicinal Chemistry 13 : 3705-3718 (2006).
 19. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? **Fernández-Ruiz J**, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Trends in Pharmacological Sciences 28 : 39-45 (2007).
 20. Cannabinoids and neuroprotection in motor-related disorders. de Lago E, **Fernández-Ruiz J**. CNS Neurol Disord Drug Targets 6 : 377-387 (2007).
 21. Cannabinoids and neuroprotection in basal ganglia disorders. Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, **Fernández-Ruiz J**. Molecular Neurobiology 36 : 82-91 (2007).
 22. Role of CB2 receptors in neuroprotective effects of cannabinoids. **Fernández-Ruiz J**, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Molecular and Cellular Endocrinology 286 : S91-S96 (2008).
 23. The endocannabinoid system in Huntington's disease. Pazos MR, Sagredo O, **Fernández-Ruiz J**. Current Pharmaceutical Design 14 : 2317-2325 (2008).
 24. Cannabinoid signaling system: Does it play a function in cell proliferation and migration, neurite elongation and guidance and synaptogenesis during brain ontogenesis? Gómez M, Hernández ML, **Fernández-Ruiz J**. Cell Adhesion & Migration 2 : 246-248 (2008).
 25. The endocannabinoid system as a target for treatment of motor dysfunction. **Fernández-Ruiz J**. British Journal of Pharmacology 156, 1029-1040 (2009)
 26. The endocannabinoid system in neuropathological states. Orgado JM, **Fernández-Ruiz J**, Romero J. International Review of Psychiatry 21, 172-180 (2009).
 27. Cannabinoids and Parkinson's disease. García-Arencibia M, García C, **Fernández-Ruiz J**. CNS Neurological Disorders and Drug Targets 8, 432-439 (2009).
 28. Cannabinoids, multiple sclerosis and neuroprotection. de Lago E, Gómez-Ruiz M, Moreno-Martet M, **Fernández-Ruiz J**. Expert Review of Clinical Pharmacology 2, 645-660 (2009).
 29. The endocannabinoid system as a target for the treatment of neuronal damage **Fernández-Ruiz J**, García C, Sagredo O, Gómez M, de Lago E. Expert Opinion on Therapeutic Targets 14, 387-404 (2010).
 30. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. **Fernández-Ruiz J**, Hernández ML, Ramos JA. CNS Neuroscience & Therapeutics 16, 72-91 (2010).
 31. Prospects for cannabinoid therapies in basal ganglia disorders. **Fernández-Ruiz J**, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garó C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. British Journal of Pharmacology 163, 1365-1378 (2011)
 32. Cannabinoids: Novel medicines for the treatment of Huntington's disease. Sagredo O, Pazos MR, Valdeolivas S, **Fernández-Ruiz J**. Recent Patents on CNS Drug Discovery 7,41-48 (2012)

33. Fármacos cannabinoides para las enfermedades neurológicas, ¿qué hay detrás? **Fernández-Ruiz J**, Revista de Neurología 54, 613-628 (2012)
34. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? **Fernández-Ruiz J**, Sagredo O, Pazos MR, García C, Pertwee RG, Mechoulam R, Martínez-Orgado J, British Journal of Clinical Pharmacology 75, 323-333 (2013)
35. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Devinsky O, Cilio MR, Cross H, **Fernández-Ruiz J**, French J, Hill C, Katz R, DiMarzo V, Jutras-Aswad D, Notcutt W, Martínez-Orgado J, Robson P, Rohrback B, Thiele E, Whalley B, Friedman D. Epilepsia 55, 791-802 (2014)
36. Endocannabinoids and neurodegenerative disorders: Parkinson's disease, Huntington's chorea, Alzheimer's disease, and others. **Fernández-Ruiz J**, Romero J, Ramos JA. Handbook in Experimental Pharmacology 231, 233-259 (2015)
37. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. **Fernández-Ruiz J**, Moro MA, Martínez-Orgado J. Neurotherapeutics 12, 793-806 (2015)
38. Cannabinoid-dopamine interactions in the physiology and pathophysiology of the basal ganglia. García MC, Palomo-Garo C, Gómez-Gálvez Y, **Fernández-Ruiz J**. British Journal of Pharmacology 173, 2069-2079 (2016)
39. Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders. Navarro G, Morales P, Rodríguez-Cueto C, **Fernández-Ruiz J**, Jagerovic N, Franco R. Frontiers in Neuroscience, 10, 68-77 (2016)
40. Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies. **Fernández-Ruiz J**, Gómez-Ruiz M, García MC, Hernández M, Ramos JA. Methods in Enzymology 593, 175-198 (2017)
41. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, **Fernández-Ruiz J**. Biochemical Pharmacology 157, 67-84 (2018)
42. The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. **Fernández-Ruiz J**. British Journal of Pharmacology 176, 1370-1383 (2019)
43. Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as neuroprotective targets. Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández ML, **Fernández-Ruiz J**. Frontiers in Molecular Neuroscience 12, 94 (2019)
44. Possible therapeutic applications of cannabis in the neuropsychopharmacology field. **Fernández-Ruiz J**, Galve-Roperh I, Sagredo O, Guzmán M. European Neuropsychopharmacology 36, 217-234 (2020)
45. Targeting the CB₂ receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Rodríguez-Cueto C, García-Toscano L, Santos-García I, Gómez-Almería M, Gonzalo-Consuegra C, Espejo-Porras F, **Fernández-Ruiz J**, de Lago E. British Journal of Pharmacology 178, 1373-1387 (2021)
46. Endocannabinoid-binding receptors as drug targets. Gómez-Cañas M, Rodríguez-Cueto C, Satta V, Hernández-Fisac I, Navarro E, **Fernández-Ruiz J**. Methods in Molecular Biology 2576, 67-94 (2023)
47. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline. Semerano A, **Fernández-Ruiz J**, Cortes-Canteli M, Moro MA. British Journal of Pharmacology 181, 755-759 (2024)
48. Enhancing drug discovery and development through the integration of Medicinal Chemistry, Chemical Biology, and academia-industry partnerships: Insights from Roche's endocannabinoid system projects Aebi J, Atz K, Ametamey SM, Benz J, Blaising J, Butini S, Campiani G, Carreira EM, Collin L, De Lago

E, Gazzi T, Gertsch J, Gobbi L, Guba W, **Fernández-Ruiz J**, Fingerle J, Haider A, He Y, Heitman LH, Honer M, Hunziker D, Kuhn B, Maccarrone M, Märki HP, Martin RE, Mohr P, Mu L, Nazaré M, Nippa DF, Oddi S, O'Hara F, Pacher P, Romero J, Röver S, Rufer AC, Schibli R, Schneider G, Stepan AF, Sykes DA, Ullmer C, Van der Stelt M, Veprintsev DB, Wittwer MB, Grether U. Chimia 78, 499-512 (2024)

49. Mouse models of amyotrophic lateral sclerosis. De Lago E, Rodríguez-Cueto C, **Fernández-Ruiz J**. Neuromethods 216, 341-363 (2025)
50. Development of novel neuroprotective agents targeting GPCR using in vitro assays. Gómez-Cañas M, Rodríguez-Cueto C, **Fernández-Ruiz J**, de Lago E. Methods in Molecular Biology 2899, 339-366 (2025)
51. Neurodegenerative diseases: pathogenesis and preclinical models for translational drug discovery. Fusaro L, Bangari DS, Pasterkamp RJ, **Fernández-Ruiz J**, Youssef SA, Sharma AK. Toxicologic Pathology 53, 364-371 (2025)
52. Ageing, neurodegeneration and the endocannabinoid system. **Fernández-Ruiz J**, Sagredo O, Gómez-Ruiz M, de Lago E. Current Topics in Behavioral Neuroscience doi:10.1007/7854_2025_597 (2025)